{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:36:56Z","timestamp":1778045816718,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fostering Joint International Research","award":["22KK0265"],"award-info":[{"award-number":["22KK0265"]}]},{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Denosumab treatment is effective for the prevention of skeletal-related events in patients with bone metastases. However, hypocalcemia has been recognized as a serious adverse effect of denosumab. This study aimed to identify the risk factors for hypocalcemia in patients with bone metastases. In this prospective open-label study, 35 patients with bone metastases to be treated with denosumab were recruited. During the 3\u00a0months follow-up, 9 patients (25.7%) experienced hypocalcemia. Higher bone turnover status at baseline was observed in patients with hypocalcemia than in those without hypocalcemia following denosumab administration (total-P1NP, TRACP-5b, and S-NTX: all p\u00a0&amp;lt;\u2009.05). Negative correlations were observed between the lowest calcium levels and baseline bone turnover markers (BTMs) levels (total-P1NP: r\u00a0=\u00a0\u22120.3987; TRACP-5b: r\u00a0=\u00a0\u22120.3664; S-NTX: r\u00a0=\u00a0\u22120.3672, all p\u00a0&amp;lt;\u2009.05). Multivariate logistic regression analysis revealed that patients with high BTMs (BAP\u2009&amp;gt;\u200932.1\u00a0\u03bcg\/L, total P1NP\u2009&amp;gt;\u200982.3\u00a0\u03bcg\/L, TRACP-5b\u2009&amp;gt;\u2009866\u00a0mU\/dL, S-NTX\u2009&amp;gt;\u200930.8\u00a0nmol\u00a0BCE\/L) had a higher risk of hypocalcemia, even after adjusting for reported risk factors, such as age, baseline calcium levels, and renal function (BAP\u2009&amp;gt;\u200932.1\u00a0\u03bcg\/L: OR\u2009=\u200910.4; total P1NP\u2009&amp;gt;\u200982.3\u00a0\u03bcg\/L: OR\u2009=\u200922.07; TRACP-5b\u2009&amp;gt;\u2009866\u00a0mU\/dL: OR\u2009=\u200936.5; S-NTX\u2009&amp;gt;\u200930.8\u00a0nmol\u00a0BCE\/L: OR\u2009=\u200939.74, all p\u00a0&amp;lt;\u2009.05). This study shows that denosumab significantly affects serum calcium levels in patients with bone metastases who have high bone turnover status. Bone turnover markers could serve as surrogate markers to predict hypocalcemia.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf013","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:23:31Z","timestamp":1737437011000},"source":"Crossref","is-referenced-by-count":2,"title":["Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab"],"prefix":"10.1093","volume":"9","author":[{"given":"Koki","family":"Tsuchiya","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa University School of Medicine , Tokyo, 142-8666 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Oshita","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital , Kanagawa, 224-0032 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Emori","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa University School of Medicine , Tokyo, 142-8666 ,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, Showa University Northern Yokohama Hospital , Kanagawa, 224-0032 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soji","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa University School of Medicine , Tokyo, 142-8666 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Showa University School of Medicine , Tokyo, 142-8666 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Ennis","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University School of Medicine , Durham, NC, 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahoko","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University School of Medicine , Durham, NC, 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa University School of Medicine , Tokyo, 142-8666 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Alman","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University School of Medicine , Durham, NC, 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-5662","authenticated-orcid":false,"given":"Koji","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa University School of Medicine , Tokyo, 142-8666 ,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, Duke University School of Medicine , Durham, NC, 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"S8","key":"2025031810231845000_ref1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+&lt;1588::AID-CNCR9&gt;3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"16","key":"2025031810231845000_ref2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"2025031810231845000_ref3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur J Cancer"},{"issue":"7","key":"2025031810231845000_ref4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5732\/cjc.012.10218","article-title":"Skeletal metastasis: treatments, mouse models, and the Wnt signaling","volume":"32","author":"Valkenburg","year":"2013","journal-title":"Chin J Cancer"},{"issue":"1","key":"2025031810231845000_ref5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"2025031810231845000_ref6","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"35","key":"2025031810231845000_ref7","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/jco.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9768","key":"2025031810231845000_ref8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"2025031810231845000_ref9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1349-7006.2008.00803.x","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci"},{"key":"2025031810231845000_ref10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/cia.S27930","article-title":"Management of bone metastases in refractory prostate cancer\u2014role of denosumab","volume":"7","author":"Paller","year":"2012","journal-title":"Clin Interv Aging"},{"issue":"2","key":"2025031810231845000_ref11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/14712598.2012.756470","article-title":"Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?","volume":"13","author":"Buonerba","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"13","key":"2025031810231845000_ref12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"issue":"9","key":"2025031810231845000_ref13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1060028014539919","article-title":"Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer","volume":"48","author":"Ikesue","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"10","key":"2025031810231845000_ref14","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","article-title":"Identification of the risk factors associated with hypocalcemia induced by denosumab","volume":"36","author":"Okada","year":"2013","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"2025031810231845000_ref15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/imj.12283","article-title":"Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure","volume":"43","author":"Farinola","year":"2013","journal-title":"Intern Med J"},{"key":"2025031810231845000_ref16","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/tcrm.S123172","article-title":"High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis","volume":"12","author":"Ishikawa","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"2025031810231845000_ref17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2025031810231845000_ref18","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/jco.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"30","key":"2025031810231845000_ref19","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/jco.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"28","key":"2025031810231845000_ref20","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/jco.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025031810231845000_ref21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2025031810231845000_ref22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025031810231845000_ref23","doi-asserted-by":"publisher","first-page":"756.e1","DOI":"10.1016\/j.ajem.2012.11.011","article-title":"Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency","volume":"31","author":"Ungprasert","year":"2013","journal-title":"Am J Emerg Med"},{"issue":"2","key":"2025031810231845000_ref24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bone.2013.04.012","article-title":"Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer","volume":"55","author":"Milat","year":"2013","journal-title":"Bone"},{"issue":"7","key":"2025031810231845000_ref25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025031810231845000_ref26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf013\/61522898\/ziaf013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/4\/ziaf013\/61522898\/ziaf013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/4\/ziaf013\/61522898\/ziaf013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:24:10Z","timestamp":1742293450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf013\/7964974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf013","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,21]]},"article-number":"ziaf013"}}